Novo Nordisk has begun phase III trial with antibody

Last summer, Novo Nordisk acquired the US-based biotech company Corvidia Therapeutics to access the antibody ziltivekimab. The pharmaceutical company has now commenced a phase III study of the drug, the company confirms in comment to MedWatch.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

In the beginning of September, Novo Nordisk started a phase III with the antibody ziltivekimab, which the company received in a million-dollar acquisition of the US-based company Corvidia Therapeutics last year, according to database Clinicaltrials.gov, which collects information about clinical studies, and Novo Nordisk confirms as much in comment to MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading